Printer Friendly

ISIS PHARMACEUTICALS APPOINTS JACQUELINE G. SIEGEL CHIEF FINANCIAL OFFICER

 ISIS PHARMACEUTICALS APPOINTS JACQUELINE G. SIEGEL
 CHIEF FINANCIAL OFFICER
 CARLSBAD, Calif., Oct. 20 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP), today announced Jacqueline G. Siegel, Ph.D., has left her post as the biotechnology analyst at Hambrecht & Quist to become vice president and chief financial officer of Isis. Dr. Siegel begins working at Isis today. Dr. Siegel is one of the most prominent figures in the biotechnology investment community. She has 10 years' experience in biomedical research and more than five years in various positions in the investment banking industry.
 "Jacqueline's combination of biotechnology and finance experience and her wealth of knowledge of the industry makes her a tremendous asset to our management team," said Stanley Crooke, M.D., Ph.D., president and chief executive officer. As CFO, the finance department reports to Dr. Siegel and she will be responsible for all corporate finance transactions, financial reporting and investor relations.
 Prior to joining Isis, Dr. Siegel, 46, has been Hambrecht & Quist's senior biotechnology analyst, where her research universe consisted of 14 companies, including both established names and IPOs. Prior to H&Q, Dr. Siegel was the biotechnology analyst for Drexel Burnham Lambert. During her financial career, Dr. Siegel had been involved in public and private securities transactions and assisted in winning new business. She also forged and maintained key alliances with public and private companies.
 Dr. Siegel's career includes the founding of a biotechnology company focused on genetically-engineered vaccines. She had been a member of the faculty at the Research Institute of Scripps Clinic in La Jolla, Calif. Dr. Siegel earned a Ph.D. in molecular biology from University of California, Berkeley, an M.B.A. from Columbia University and an A.B. in chemistry from Bryn Mawr College.
 Isis Pharmaceuticals, Inc. based in northern San Diego County, is engaged in the discovery, development and marketing of novel human therapeutic products based on antisense oligonucleotides. Isis is in Phase I human clinical trials on a new drug, the first antisense drug to be administered to humans, to treat human papillomavirus.
 -0- 10/20/92
 /CONTACT: B. Lynne Parshall, Esq., of Isis, 619-931-9200; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Isis/
 (ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU: PER


GK-AH -- NY028 -- 2105 10/20/92 10:06 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 20, 1992
Words:384
Previous Article:BARRETT RESOURCES CORP. ANNOUNCES MULTIFIELD DEVELOPMENT DRILLING PROGRAM AND PARTICIPATION IN A HORIZONTAL DRILLING PROGRAM
Next Article:LEADING SOFTWARE VENDORS ANNOUNCE DRDA PRODUCTS AND SUPPORT
Topics:


Related Articles
ISIS PHARMACEUTICALS APPOINTS JOSEPH WENDER TO BOARD
ISIS PHARMACEUTICALS NAMES DANIEL L. KISNER, M.D., PRESIDENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters